key: cord-0943727-dng3ef3x authors: González-Domínguez, Irene; Martínez, Jose Luis; Slamanig, Stefan; Lemus, Nicholas; Liu, Yonghong; Lai, Tsoi Ying; Carreño, Juan Manuel; Singh, Gagandeep; Schotsaert, Michael; Mena, Ignacio; McCroskery, Stephen; Coughlan, Lynda; Krammer, Florian; García-Sastre, Adolfo; Palese, Peter; Sun, Weina title: Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice date: 2022-03-22 journal: bioRxiv DOI: 10.1101/2022.03.21.485247 sha: c42e5ff18f3d5c72c8148b7d25b0cceeb48ca8b6 doc_id: 943727 cord_uid: dng3ef3x Equitable access to vaccines is necessary to limit the global impact of the coronavirus disease 2019 (COVID-19) pandemic and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. In previous studies, we described the development of a low-cost vaccine based on a Newcastle Disease virus (NDV) expressing the prefusion stabilized spike protein from SARS-CoV-2, named NDV-HXP-S. Here, we present the development of next-generation NDV-HXP-S variant vaccines, which express the stabilized spike protein of the Beta, Gamma and Delta variants of concerns (VOC). Combinations of variant vaccines in bivalent, trivalent and tetravalent formulations were tested for immunogenicity and protection in mice. We show that the trivalent preparation, composed of the ancestral Wuhan, Beta and Delta vaccines, substantially increases the levels of protection and of cross-neutralizing antibodies against mismatched, phylogenetically distant variants, including the currently circulating Omicron variant. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the 48 current coronavirus disease 2019 . Since the beginning of the pandemic, the 49 emergence of new variants of concern (VOC) has threatened the protection conferred by CoV-2 spike protein stabilized in its prefusion-conformation by the introduction of six proline 71 mutations (HexaPro, HXP-S) [4, 12] and elimination of the furin cleavage site. NDV-HXP-S 72 can be used as live vaccine [11, 13, 14] or as an inactivated vaccine [11, 15] The immunogenicity and in vivo protection of the new NDV-HXP-S Beta and Gamma vaccine 108 candidates was first evaluated in BALB/c mice transduced with a non-replicating human 109 adenovirus 5 expressing human angiotensin-converting enzyme 2 (Ad5-hACE2) ( Figure 3A) . A 110 two-dose intramuscular (IM) vaccination regimen with a total protein content of 1 µg per mouse 111 of purified NDV-HXP-S vaccine candidate with a 3-week period between doses was followed. Three weeks after the boost, BALB/c mice were transduced by intranasal (IN) administration of 113 the Ad5-hACE2 and five days later mice were challenged with SARS-CoV-2 viruses via the IN 114 route, as previously described [18] . Two days after challenge, viral titers in the lung 115 homogenates were quantified by plaque assays. Vaccination with wild type NDV was used as 116 negative control ( Figure 3B ). A viral titer reduction of 2,237-fold, 2,015-fold and 285-fold was obtained in the homologous 118 challenge using monovalent vaccination regimens with Wuhan, Beta and Gamma NDV-HXP-S vaccines compared to the negative control, respectively (p.value <0.05 versus the neg.control, 120 Figure 3C ). Heterologous protection with Wuhan NDV-HXP-S against Beta and Gamma 121 challenge was observed with a viral titer reduction of 51-fold and 120-fold compared to the 122 negative control, respectively, in agreement with previous studies [11] . Beta NDV-HXP-S 123 vaccine showed cross-protection against the Gamma variant challenge, and vice versa. However, 124 an asymmetric weaker protection of Beta and Gamma vaccines was observed against the Wuhan 125 challenge. Together with the in vivo challenge study, mice were bled 3-weeks after boost to measure the 127 spike-specific IgG levels. Antibody titers after vaccination against Wuhan, Beta and Gamma 128 spikes were compared in Figures 3D-F Following the characterizations of Beta and Gamma NDV-HXP-S vaccines, the Delta VOC 142 appeared in India and rapidly replaced the other variants ( Figure 1B ). When the Delta vaccine 143 construct was generated, a second mouse immunization and challenge study was performed 144 testing vaccine formulations containing the Delta component ( Figure 4A ). Based on the 145 previous results, the following groups were evaluated: monovalent Wuhan, monovalent Delta, 146 bivalent Wuhan and Delta, sequential vaccination with a first dose of Wuhan followed by Delta, 147 trivalent (Wuhan, Delta and Beta) and tetravalent (Wuhan, Delta, Beta and Gamma). In all cases, 148 the vaccination dose was 1 µg of total protein ( Figure 4B ). In this study, we wanted to test not only the protection against homologous challenge, but also 150 against a phylogenetically distant SARS-CoV-2 variant, which is unmatched to any vaccine 151 component. To do so, animals in each group were divided into 3 subgroups and challenged with 152 Wuhan, Delta and Mu variants ( Figure 4C ). As expected, Wuhan and Delta showed protection 153 against its homologous virus challenge. Of note, bivalent, trivalent and tetravalent vaccines 154 showed comparable levels of protection as the homologous monovalent vaccines against 155 Washington 1 (Wuhan-like) and Delta challenges. Viral titers were reduced in trivalent condition 21,845-fold and 3,119-fold compared to the negative control in Wuhan and Delta 157 challenges, respectively. However, sequential vaccination regimen was shown to be less 158 protective, with only a 54-fold mean titer reduction in Delta challenge. In the case of the Mu 159 challenge, trivalent formulation was proven to be the best with a titer reduction of 594-fold 160 ( Figure 4C , p.value <0.0001 compared to the neg. control). This reduction was 2.4 times higher 161 than any of the other vaccination strategies tested including that of the tetravalent preparation 162 (for discussion see below). Considering the new emergence of the Omicron variant, we decided to compare the neutralizing 164 activity of post-boost serum antibodies against the Wuhan, Delta, Beta and Omicron variants in 165 authentic virus neutralization assays ( Figure 4D) . A similar 50% inhibitory dilution (ID 50 ) was 166 obtained against Wuhan in all vaccinated groups except for Delta (0.4-fold compared to Wuhan). In the case of Delta microneutralization, the neutralizing activity was increased in the trivalent 168 and tetravalent (2.0-fold and 2.5-fold compared to the ancestral strain, respectively), whereas 169 Wuhan alone and sequential showed a smaller neutralizing activity . A similar ID 50 was 170 obtained against Beta with monovalent, bivalent, and sequential strategies, whereas it was 171 increased 2.5-fold and 2.7-fold in the trivalent and tetravalent groups, respectively. Little Wuhan and Delta spike-specific IgG levels were comparable among all vaccination groups. In 184 the case of Beta, an increase of 2.9-fold and 1.9-fold were observed in the trivalent and 185 tetravalent vaccination compared to monovalent Wuhan group, respectively. An increase was 186 also observed against Alpha (1.7-fold) and Gamma spikes (1.5-fold) in the trivalent condition 187 ( Figure 5A ). Finally, vaccinated mice sera were also tested against Omicron spike. Omicron Evidence for retained spike-binding and neutralizing 614 activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA 615 vaccine recipients. EBioMedicine Multiple SARS-CoV-2 variants escape 617 neutralization by vaccine-induced humoral immunity Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 620 neutralization Tracking Coranavirus Vaccination Around the World Activity of convalescent and vaccine serum against SARS-626 CoV-2 Omicron Coronavirus Pandemic (COVID-19) Omicron sub-lineage BA.2 may have "substantial growth 632 advantage Omicron and S-gene target failure cases in the highest COVID-19 634 case rate region in Canada Methods for the detection and characterisation of SARS-CoV-2 636 variants -first update Global production capacity of seasonal and pandemic 639 influenza vaccines in 2019. Vaccine A Newcastle disease virus expressing a stabilized spike protein 641 of SARS-CoV-2 induces protective immune responses Structure-based design of prefusion-stabilized SARS-CoV-2 644 spikes Safety and Immunogenicity Analysis of a Newcastle Disease 646 Expressing the Spike Protein of SARS-CoV-2 in Sprague 647 Dawley Rats. Front Immunol Safety and Immunogenicity of a Newcastle Disease 649 Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-650 HEXAPRO (Patria), in Pigs. mBio Safety and immunogenicity of an inactivated 652 recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: 653 Interim results of a randomised Safety and immunogenicity of a live recombinant Newcastle disease 666 virus-based COVID-19 vaccine (Patria) administered via the intramuscular or 667 intranasal route: Interim results of a non-randomized open label phase I trial in 668 Mexico. medRxiv Safety and Immunogenicity of An Egg-Based Inactivated 670 Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim 671 Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam. 2022 Comparison of transgenic and adenovirus hACE2 673 mouse models for SARS-CoV-2 infection SARS-CoV-2 vaccines in development Homologous or heterologous booster of inactivated vaccine 678 reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies mRNA-1273 or mRNA-Omicron boost in vaccinated macaques 681 elicits comparable B cell expansion, neutralizing antibodies and protection 682 against Omicron Fitness selection of hyperfusogenic measles virus F proteins 684 associated with neuropathogenic phenotypes A Newcastle Disease Virus (NDV) Expressing a Membrane-687 Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine Rescue of recombinant 690 Newcastle disease virus from cDNA A serological assay to detect SARS-CoV-2 seroconversion in 692 humans SARS-CoV-2 Seroconversion in Humans: A Detailed 694 Protocol for a Serological Assay, Antigen Production, and Test Setup Newcastle disease virus (NDV) expressing the spike protein of 700 SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine Nextstrain: real-time tracking of pathogen evolution TreeTime: Maximum-likelihood 705 phylodynamic analysis